News
  • Engineering PEG-based hydrogels to foster efficient endothelial network formation in free-swelling and confined microenvironments
    Engineering PEG-based hydrogels to foster efficient endothelial network formation in free-swelling and confined microenvironments June 8,2020.
    Engineering PEG-based hydrogels can efficiently foster endothelial network formation in free-swelling and confined microenvironments Polyethylene glycol (PEG) and its derivatives are among the few polymers approved by the US FDA that can be used in biomedical products. The PEGl-based hydrogel has excellent flexibility and biocompatibility. Some PEG hydrogels can not only be degraded, but also can form bioactive site through modifying the connexins in a chemical way. In vitro tissue engineered models are expected to have significant impact on disease modeling and preclinical drug development. Reliable methods to induce microvascular networks in such microphysiological systems are needed to improve the size and physiological function of these models. By systematically engineering several physical and biomolecular properties of the cellular microenvironment (including crosslinking density, polymer density, adhesion ligand concentration, and degradability), the author Alexander Brown establish design principles that describe how synthetic matrix properties influence vascular morphogenesis in modular and tunable hydrogels based on commercial 8-arm poly (ethylene glycol) (PEG8a) macromers. The author applies these design principles to generate endothelial networks that exhibit consistent morphology throughout depths of hydrogel greater than 1 mm. These PEG8a-based hydrogels have relatively high volumetric swelling ratios (>1.5), which limits their utility in confined environments such as microfluidic devices. To overcome this limitation, the author mitigates swelling by incorporating a highly functional PEG-grafted alpha-helical poly (propargyl-l-glutamate) (PPLGgPEG) macromer along with the canonical 8-arm PEG8a macromer in gel formation. This hydrogel platform supports enhanced endothelial morphogenesis in neutral-swelling environments. Finally, the author incorporates PEG8a-PPLGgPEG gels into microfluidic devices and demonstrates improved diffusion kinetics and microvascular network formation in situ compared to PEG8a-based gels. [1] Brown A ,  He H ,  Trumper E , et al. Engineering PEG-based hydrogels to foster efficient endothelial network formation in free-swelling and confined microenvironments[J]. Biomaterials, 2020, 243:119921. If there is any copyright infringement, please contact us and we will remove the content at the first time. Sinopeg provide various NW poly(ethylene glycol) (PEG) products: 2KDa, 5KDa, 10KDa, 20KDa, etc. Products: Linear Monofunctional PEGs Linear Bifunctional PEGs Linear Heterofunctional PEGs Branched PEGs Multi-Arm Functional PEGs Functionally Grafted PEGs
    View More
  • Invitation Letter - CPHI Milan 2024 #6C92
    Invitation Letter - CPHI Milan 2024 #6C92 September 5,2024.
    We are pleased to invite you to join us at the CPHI Milan 2024, taking place on October 8-10, 2024, in Milan, Italy. SINOPEG will be showcasing our latest products and technologies, and we are eager to share our innovations and achievements. Event Details: Event Name: CPHI Milan 2024 Date: October 8-10, 2024 Location: Fiera Milano, Italy SINOPEG is committed to providing high-quality products and excellent services. This exhibition presents a fantastic opportunity for us to discuss potential collaborations, share industry insights, and present our innovative solutions. We warmly invite you to visit our booth #6C92, and we look forward to the opportunity to connect with you. Should you need any further information, please feel free to contact us. Thank you, and we hope to see you there!
    View More
  • Excipients for LNP Delivery Systems
    Excipients for LNP Delivery Systems January 22,2024.
    Lipid nanoparticle (LNP) delivery systems are widely used in the fields of gene therapy and vaccines.However, to achieve effective gene delivery and vaccine delivery, not only suitable carriers and nucleic acids or antigens need to be selected, but also excipients for LNP delivery systems are needed.These excipients play a key role in stability, transparency, protective effect, and charge capacity. Firstly, stability is an important characteristic of excipients for LNP delivery systems.Excipients interact with lipid components, increasing the stability of LNP.For example, polyethylene glycol (PEG) is one of the commonly used excipients, which can form a stable layer of polymer by covering the surface of LNP.This polymer layer helps to reduce protein and cell adsorption and provides additional stability, thereby prolonging the circulation life of LNP. Secondly, transparency is an important factor to be considered when designing LNP delivery systems.Transparency can affect the preparation of LNP and the visualization of the internal structure.Therefore, excipients are usually selected for their characteristics of lower absorption and scattering of light to obtain clear imaging and accurate structural analysis. In addition, excipients for LNP delivery systems can also provide protection, protecting nucleic acids or antigens from degradation. For example, cholesterol is a common excipient that can be inserted into LNP to form a barrier that protects the nucleic acid or antigen.This protective layer can prevent the nucleic acid or antigen from being attacked by enzymes and help improve delivery efficiency and immune activation. In addition, charge is also an important characteristic of excipients.Charge can affect the interaction between LNP and target cells and delivery efficiency.For example, some excipients can regulate the charge state on the surface of LNP to improve its adsorption and cell uptake, thus improving delivery effect. In summary, excipients in LNP delivery systems play an important role in gene therapy and vaccine research.By selecting appropriate excipients, the stability, transparency, protective effect and charge of LNP can be optimized to achieve efficient gene delivery and vaccine delivery.Researchers will continue to develop new excipients to further improve the performance of LNP delivery systems and promote the development of gene therapy and vaccine research. Lipids that has been registered with DMF: Ionizable Cationic Lipid DLin-MC3-DMA SM-102 (HUO) ALC-0315 (DHA) DHA-1 (ALC-0315 analogue) PEGylated Lipids mPEG-DMG-2K ALC-0159 (mPEG-DTA) mPEG-DTA-1-2K (ALC-0159 analogue) Neutral Phospholipid DSPC DOPE Sterol Lipids Cholesterol (Plant) Click here for more lipid products
    View More
first page 11 12 13 14 15 16 17 18 19 20 last page

A total of 20 pages

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.

Home

Products

News

contact